Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542154 | 0.83 | ALPL (0.52) | ALPLPTPN1ADRA2ANPY5RMCHR1 | |
| SCHEMBL29843178 | 0.83 | ALPL (0.52) | ALPLPTPN1ADRA2ANPY5RMCHR1 | |
| SCHEMBL1023819 | 0.83 | ALPL (0.52) | ALPLPTPN1ADRA2ANPY5RMCHR1 | |
| SCHEMBL16186184 | 0.83 | ALPL (0.49) | ALPLPTPN1ADRA2ANPY5RMCHR1 | |
| SCHEMBL2831975 | 0.83 | PTPN1 (0.51) | ALPLPTPN1ADRA2ANPY5RMCHR1 | |
| SCHEMBL3018907 | 0.83 | ALPL (0.58) | ALPLPTPN1ADRA2ANPY5RMCHR1 | |
| Hydrochloric Acid SCHEMBL27749584 | 0.82 | ALPL (0.51) | ALPLPTPN1ADRA2ANPY5RMCHR1 | |
| SCHEMBL3019244 | 0.81 | ALPL (0.57) | ALPLPTPN1ADRA2ANPY5RMCHR1 | |
| SCHEMBL13461893 | 0.81 | CA1 (0.43) | ALPL | |
| SCHEMBL4639515 | 0.80 | L3MBTL1 (0.51) | ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013001297-A1 | BINDING INHIBITORS OF THE BETA.TRANSDUCIN REPEAT - CONTAINING PROTEIN | ITI SCOTLAND LIMITED (GB) | 2013-01-03 | — | — | WO | disclosed |
| US-8071795-B2 | Hypoxia inducible factor (Hif); for modulating mRNA translation within cells; prevents excessive vascularization | EMORY UNIVERSITY (US) | 2011-12-06 | — | — | US | disclosed |
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080226622-A1 | Hif Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-18 | — | — | US | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1585739-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226622-A1 | Hif Inhibitors | HIF1AN, HIF1A, EGLN3 | ALPL 3307/4885PTPN1 3520/4885ADRA2A 4090/4885 |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | GCK, GCKR, GALK1 | ALPL 1695/4885PTPN1 2956/4885ADRA2A 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.